Navigation Links
Vaxart Demonstrates Efficacy of Oral Avian Flu Vaccine in Preclinical Studies
Date:10/24/2008

eve a robust immune response that is focused on the targeted pathogen rather than the delivery vehicle. This approach addresses the problems that have plagued vector-based vaccination and also allows us to create different vaccines simply by switching out the antigen."

In the recent study, Vaxart tested the ND1 vaccine using oral administration to ferrets, widely recognized as the most predictive animal model for influenza research. Researchers administered vaccine at the start of the study and at 4 weeks. At 8 weeks, researchers measured antibody responses, then monitored survival following direct nasal exposure of 10 times the median lethal dose of H5N1 avian influenza virus. Seventy-five percent (6 of 8) of oral vaccinated ferrets developed antibody levels of 1:200 or greater, survived the challenge and were healthy as demonstrated by weight gain after challenge, while all 12 control ferrets either died (67 percent) or became very ill (33 percent). These results, if confirmed in human immunogenicity studies, compare well to the approved, injectable avian flu vaccine that achieved protective antibody levels in 45 percent of human subjects.

In a previous study conducted in mice, 6 of 6 mice vaccinated orally with ND1 survived H5N1 avian flu challenge, while 8 of 8 unvaccinated mice died. Based on these results, Vaxart plans to proceed to an investigational new drug application (IND) and begin clinical studies of the avian flu vaccine in 2009. The company is also developing an annual flu vaccine.

"To date, efforts to develop a broadly-applicable oral vaccine platform have not been successful, but the advantages of a modular approach for vaccine development are compelling, particularly for influenza," said Mark Backer, PhD, Vaxart CEO. "We can provide a vaccine that matches a new outbreak strain months faster than current approaches."

"These results are encouraging. An oral vaccine for pandemic flu would be a great help in rapid distributi
'/>"/>

SOURCE Vaxart Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
2. SuperGens MP-470 Demonstrates Clinical Tumor Regression When Combined with Standard of Care Chemotherapy
3. SAFC Hitech(TM) Successfully Demonstrates Device-Quality GST Precursors For Phase Change Memory Applications
4. Grid Dynamics Demonstrates Linear Scalability up to 512 Nodes with GridGain Software on Amazon EC2 Cloud
5. First semiconductor-based PET scanner demonstrates potential to aid in early diagnosis of disease
6. SemBioSys Demonstrates Functionality of its Safflower Produced Apo AI(Milano)
7. ASCO 2008: Tumor-Targeted Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Metastatic Pancreatic Cancer
8. Oral PBI-1402 Demonstrates Significant Activity in Chemotherapy-Induced Anemia Phase II Clinical Trial
9. ANX-530 Demonstrates Equivalent Pharmacokinetics to Navelbine(R) in a Registrational Bioequivalence Clinical Study
10. Bringing a New Rhythm to Cardiology Workflow: Siemens Demonstrates Answers to Cardiologys Toughest Questions
11. 960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotechs Novel 5-FU Central Venous Catheter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... FRANCISCO, Calif. , Nov. 24, 2014   Veracyte, ... Bonnie H. Anderson , president and chief executive officer, ... Jaffray 26 th Annual Healthcare Conference on Tuesday, December ... York . The live audio webcast and ... http://investor.veracyte.com . Please connect to the website at least ...
(Date:11/24/2014)... Nov. 24, 2014  Spherix Incorporated (Nasdaq: ... to the fostering and monetization of intellectual property, ... Telecommunications Ltd.,  Case No. 3:13-cv-03494-M and  Spherix v. ... both in the United States District Court for ... . On November 21, 2014 ...
(Date:11/22/2014)... 21, 2014 Prominent academics, leaders ... gather on December 3rd at Genetic Rx, a ... GeneticRx will take place at the Joseph B. ... will discuss the present and future of genetic ... and gene editing—as well as the treatment of ...
(Date:11/22/2014)... November 22, 2014 Respiratory therapy ... the proper management of life-like respiratory ailments using ... devices . Grand Rapids-based, Michigan Instruments Inc. developers ... two of the respiratory simulation units to the ... Grand Valley and Muskegon Community College are collaborating ...
Breaking Biology Technology:Veracyte to Present at the Piper Jaffray 26th Annual Healthcare Conference 2Markman Hearing Held as Scheduled in VTech and Uniden Cases 2Pioneering Academics and Key Industry Leaders to Discuss Rare Diseases and the Emergence of New Genetic Medicines at Genetic Rx on December 3rd 2Michigan Instruments Donates Two Respiratory Simulation Training and Test Lung (TTL) Devices to Grand Valley State University 2Michigan Instruments Donates Two Respiratory Simulation Training and Test Lung (TTL) Devices to Grand Valley State University 3
... signed into law Senate Bill 338, which is designed ... in the way of University of Wisconsin researchers. , ... turn research ideas into potential business opportunities. He said ... faculty and staff try to start businesses based on ...
... San Francisco or Boston, and youre on the verge of investing ... right: The management team is in place, the business plan is ... a lawyer steps into the room, clears her throat and asks ... not write that check, she says, until you learn more about ...
... - Are state government information technology consolidation projects ... Miszewski, the CIO for the State of Wisconsin, has ... are not unusual for large state projects. He has ... government CIOs, but are cost overruns, implementation delays, and ...
Cached Biology Technology:Why repealing the shareholder wage lien law makes sense 2Why repealing the shareholder wage lien law makes sense 3State IT failures are not inevitable 2State IT failures are not inevitable 3State IT failures are not inevitable 4State IT failures are not inevitable 5
(Date:11/15/2014)... -- While we may still be a few years away from ... to gain instant access to all that ailed his patients, ... tablets for monitoring and measuring our health are cropping up ... a tad Orwellian to some, but a new survey suggests ... opportunities into their healthcare regime. These are some ...
(Date:11/7/2014)... Calif. , Nov. 7, 2014  In conjunction with ... Police Departments, The Community Foundation of the Verdugos ... DNA JUSTICE PROJECT," a $250,000 initiative to keep ... initial phase. In its first six months of existence, the ... needed evidence support for local law enforcement. "Because ...
(Date:11/6/2014)... Baltimore, MD, November 6, 2014 - Insilico Medicine, ... in aging and age related diseases announced a ... medicine of cancer, Champions Oncology, Inc (OTC: CSBR). ... genomics for personalized medicine, but Champions Oncology,s TumorGraft ... can validate the chemotherapy regimen experimentally generating vast ...
Breaking Biology News(10 mins):Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2
... researchers sometimes need to put on the hip waders, pull ... compares to the real world. According to a Stanford University ... of Science, Mother Nature is more predictable than lab experiments ... stickleback, nature took advantage of the same genetic trick time ...
... scientists report in the journal Nature that the "missing" ... up by splicing together sequences in distant parts of ... Dieter Söll in the Department of Molecular Biophysics and ... with a known genome sequence. Nanoarchaeum equitans, is a ...
... the University of Cincinnati (UC) College of Medicine have ... stroke known as cerebral vasospasm. , A constriction of ... occurs three to 10 days following a massive brain ... who survive the initial stroke develop vasospasm, and 40 ...
Cached Biology News:Same mutation aided evolution in many fish species, Stanford study finds 2Same mutation aided evolution in many fish species, Stanford study finds 3Researchers find missing genes of ancient organism 2Researchers discover molecule that causes secondary stroke 2
... OPTIMA is a fully automated microplate ... science labs in academia and industry. ... principles: Fluorescence Intensity including ... Fluorescence including DELFIATM High-Performance ...
... CYCLES. An assay kit designed to detect ... PARP is an enzyme implicated in DNA ... is cleaved by caspase-3. Cleavage of PARP ... kDa is a hallmark of apoptosis. Each ...
... The Digital Clamp One can operate as a ... a Conductance (Dynamic) Clamp in electrophysiology research applications. ... as conventional analog equipment. • ... very recent advances in the capabilities of Digital ...
... DH-2000, but comes with a shutter (controlled via ... Hz) The DH-2000 Deuterium Tungsten ... deuterium and tungsten halogen light sources in a ... a powerful, stable output from 215-200 nm. In ...
Biology Products: